MedAdvisor Limited (AU:MDR) has released an update.
MedAdvisor Limited has reported a substantial increase in 3Q FY24 revenues, boasting a 42.4% rise to $24.2 million, with significant growth in the US and ANZ markets. The company’s year-to-date revenue outstripped the previous full year’s figure, with gross profit also seeing a notable 48.5% increase this quarter. MedAdvisor’s latest initiatives include the implementation of pharmacy transaction fees in Australia and a new partnership aimed at delivering AI-driven patient engagement through pharmacies.
For further insights into AU:MDR stock, check out TipRanks’ Stock Analysis page.
